Cullinan Oncology
CGEM
70 hedge funds and large institutions have $1.3B invested in Cullinan Oncology in 2021 Q1 according to their latest regulatory filings, with 70 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
75.66% more ownership
Funds ownership: 0% → 75.66% (+76%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$321M |
| 2 |
FCMV
Foresite Capital Management V
Larkspur,
California
|
+$111M |
| 3 |
CA
CHI Advisors
New York
|
+$89.4M |
| 4 |
BG
Baupost Group
Boston,
Massachusetts
|
+$74.5M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$49.5M |
Top Sellers
CGEM Hedge Fund Activity: Q1 2021 in Review
70 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Cullinan Oncology (CGEM) for Q1 2021, worth a combined $1.3B.
Buyers outnumbered sellers: 70 funds opened new CGEM positions and 0 closed out — a net gain of 70 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was MPM BioImpact, opening a new position worth an estimated $321M.
- 70 institutional investors held Cullinan Oncology (CGEM) as of Q1 2021, up from 0 in Q4 2020.
- Funds reported $1.3B of Cullinan Oncology stock for Q1 2021.
- 70 funds opened new Cullinan Oncology positions in Q1 2021 and 0 closed out, a net change of +70 holders.
- The largest Cullinan Oncology buyer in Q1 2021 was MPM BioImpact, an estimated $321M added.
Based on aggregated 13F filings for Q1 2021.